ViropticCompany: King Pharmaceuticals
Approval Status: Approved February 1998
Treatment for: inflammation of the cornea due to herpes simplex virus
Areas: Immune System; Eye Health / Ophthalmology; Pediatrics
Viroptic Oththalmic Solution (trifluridine) 1% has been approved for use in children (ages 6+) as a treatment for inflammation of the cornea caused by the herpes simplex virus. The antiviral agent was previously approved for use in adults.
Viroptic Drug Information
The Viroptic drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.